This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 111/22/2898    most recent CIRCULATIONAHA.104.526673v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sweeney, M. O. Articles by Stark, A. J. Search for Related Content PubMed PubMed Citation Articles by Sweeney, M. O. Articles by Stark, A. J. Related Collections Arrhythmias, clinical electrophysiology, drugs Ablation/ICD/surgery Primary prevention Secondary prevention

(Circulation. 2005;111:2898-2905.)
© 2005 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients

Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial

Michael O. Sweeney, MD; Mark S. Wathen, MD; Kent Volosin, MD; Ismaile Abdalla, MD; Paul J. DeGroot, MS; Mary F. Otterness, MS; Alice J. Stark, RN, PhD

From Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (M.O.S.); Vanderbilt University Medical Center, Nashville, Tenn (M.S.W.); University of Pennsylvania, Philadelphia, Pa (K.V.); Amarillo Heart Group, Amarillo, Tex (I.A.); and Medtronic, Inc, Minneapolis, Minn (P.J.D., M.F.O., A.J.S.).

Correspondence to Michael O. Sweeney, MD, Cardiac Arrhythmia Service, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail mosweeney{at}partners.org

Received November 30, 2004; revision received February 3, 2005; accepted March 1, 2005.

Background— Implantable cardioverter defibrillators (ICDs) reduce mortality in primary and secondary prevention. Quality of life, mortality, appropriate therapies for specific ventricular rhythms, and inappropriate therapies for supraventricular tachycardia (SVT) were compared among 582 patients (primary prevention=248; secondary prevention=334) in PainFREE Rx II, a 634-patient prospective, randomized study of antitachycardia pacing or shocks for fast ventricular tachycardia (FVT).

Methods and Results— ICDs were programmed identically with 3 zones (ventricular tachycardia [VT] <188 bpm; FVT=188 to 250 bpm; ventricular fibrillation [VF] >250 bpm) but randomized to antitachycardia pacing or shock as initial therapy for FVT. All treated episodes with electrograms were adjudicated. Primary prevention patients had lower ejection fractions and more coronary artery disease. ß-Blocker use, antiarrhythmic drug use, and follow-up duration were similar. Over 11±3 months, 1563 treated episodes were classified as VT (n=740), FVT (n=350), VF (n=77), and SVT (n=396). The distribution of VT, FVT, and VF was not different between primary and secondary prevention patients (respectively, VT 52% versus 54%, FVT 35% versus 35%, and VF 14% versus 10%). More secondary prevention patients had appropriate therapies (26% versus 18%, P=0.02), but among these patients, the median number of episodes per patient was similar. Inappropriate therapies occurred in 15% of both groups and accounted for similar proportions of all detected and treated episodes (46% in primary prevention patients versus 34% in secondary prevention patients, P=0.09). Quality of life improved modestly in both groups, and mortality was similar.

Conclusions— Primary prevention patients are slightly less likely to have appropriate therapies than secondary prevention patients, but episode density is similar among patients with appropriate therapies. SVT resulted in more than one third of therapies in both groups, but quality of life and mortality were similar.

Key Words: death, sudden • mortality • defibrillators, implantable • tachycardia, ventricular • tachycardia, supraventricular

This article has been cited by other articles:

				S. P. Bhavnani, C. I. Coleman, C. M. White, C. A. Clyne, R. Yarlagadda, D. Guertin, and J. Kluger Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy Europace, July 1, 2008; 10(7): 854 - 859. [Abstract] [Full Text] [PDF]

				A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62. [Full Text] [PDF]

				A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation, May 27, 2008; 117(21): e350 - e408. [Full Text] [PDF]

				J. B. Johansen, S. S. Pedersen, H. Spindler, K. Andersen, J. C. Nielsen, and P. T. Mortensen Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients Europace, May 1, 2008; 10(5): 545 - 551. [Abstract] [Full Text] [PDF]

				J. P. Daubert, W. Zareba, D. S. Cannom, S. McNitt, S. Z. Rosero, P. Wang, C. Schuger, J. S. Steinberg, S. L. Higgins, D. J. Wilber, et al. Inappropriate Implantable Cardioverter-Defibrillator Shocks in MADIT II: Frequency, Mechanisms, Predictors, and Survival Impact J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1357 - 1365. [Abstract] [Full Text] [PDF]

				S. S Pedersen, D. A. Theuns, A. Muskens-Heemskerk, R. A. Erdman, and L. Jordaens Type-D personality but not implantable cardioverter-defibrillator indication is associated with impaired health-related quality of life 3 months post-implantation Europace, August 1, 2007; 9(8): 675 - 680. [Abstract] [Full Text] [PDF]

				P. J. Zimetbaum A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator JAMA, May 2, 2007; 297(17): 1909 - 1916. [Abstract] [Full Text] [PDF]

				M. H. Schoenfeld Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist Circulation, February 6, 2007; 115(5): 638 - 653. [Full Text] [PDF]

				C. Ypenburg, L. van Erven, G. B. Bleeker, J. J. Bax, M. Bootsma, M. C. Wijffels, E. E. van der Wall, and M. J. Schalij Benefit of Combined Resynchronization and Defibrillator Therapy in Heart Failure Patients With and Without Ventricular Arrhythmias J. Am. Coll. Cardiol., August 1, 2006; 48(3): 464 - 470. [Abstract] [Full Text] [PDF]

				M. O. Sweeney Overcoming the Defects of a Virtue: Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study Circulation, June 27, 2006; 113(25): 2862 - 2864. [Full Text] [PDF]